Vaccine Efficacy IPD and Pneumonia
|
|
- Jade Phelps
- 5 years ago
- Views:
Transcription
1
2 Vaccine Efficacy IPD and Pneumonia Hanna Nohynek, MD PhD National Public Health Institute Helsinki, Finland for 3rd Regional Pneumococcal Symposium Istanbul, Turkey February 13-14, 2008
3 Vaccine efficacy (VE) VE = 100 x (1 RR) = 100 x (1 AR v / AR UV )
4 Composition of Pneumococcal Conjugate Vaccines in trials Capsular polysaccharide of 7-13 pneumococcal serotypes, conjugated to Carrier protein CRM 197 PD (D-protein of Haemophilus influenzae) OMPC D or T
5 Invasive Pneumococcal Disease
6 Randomized controlled trials of PCV against IPD PCV-7 4, 6B, 9V, 14, 18C, 19F, 23F PCV-9 + 1, 5 N =
7 Incidence of IPD / PY in children < 2 year of age in trial sites HIVseveral fold higher in HIV+
8 Efficacy of PCV against vaccine type (VT) IPD is established for PncCRM NCKP ZA HIV (-) 84.6 Gambia 77.0 Native Am 76.8 ZA HIV (+) PCV-7; PCV Vaccine Efficacy (PP, 95%CI)
9 References NCKP / California, the US Black S, Shinefield H, et al. PIDJ 2000; 19 (3): South Africa HIV(-) and HIV(+) Klugman KP, Madhi SA, et al. NEJM 2003; 349 (14): Lucero MG, Dulalia VE, et al. Cochrane Database of Systematic Reviews 2004, Issue 4. Art. No.: CD DOI: / CD The Gambia Cutts FT, Zaman SMA, et al. Lancet 2005; 365: American Indian, the US O Brien KL, Moulton LH, et al. Lancet 2003; 362:
10 N = 54 in vaccinees N = 180 in controls Meta analysis of the efficacy of conjugate vaccines against invasive pneumococcal disease Klugman KP, Cutts F, Adegbola RA, Black S, Madhi SA, O Brien KL, Santosham M, Shinefield H, Sterne JAC In Press
11 Meta-analysis main message: PCV efficacious (VE ITT) against vaccine-serotype specific IPD in Randomized Controlled (RC) Trials 7v vaccine type IPD in HIV negative Study NCKP (2000) Native American (2003) South Africa HIV - (2007) The Gambia (2005) M-H Overall (p = 0.251) D+L Overall RR (95% CI) 0.06 (0.02, 0.20) 0.17 (0.04, 0.78) 0.23 (0.07, 0.81) 0.24 (0.11, 0.51) 0.15 (0.09, 0.25) 0.16 (0.08, 0.31) Vaccine efficacy (%) 94 (80, 98) 83 (22, 96) 77 (19, 93) 77 (49, 89) 85 (75, 91) 84 (69, 92) Risk ratio
12 Meta-analysis PCV efficacy against individual vaccineserotype specific IPD in RCTrials Serotype Events Vaccinees N = Events Controls N = Vaccine Efficacy (95%CI) (-65 to 93) 6B ( 47 to 90) 9V (-23 to 80) (59 to 91) 18C ( 3 to 89) 19F (13 to 82) 23F ( 3 to 78)
13 Meta-analysis PCV efficacy against individual vaccineserotype specific IPD in RCTrials Serotype Events Vaccinees N= Events Control N= Vaccine Efficacy (95%CI) (-120 to 76) N= N= (-65 to 93) (26 to 96) N= N= B ( 47 to 90) 9V (-23 to 80) (59 to 91) 18C ( 3 to 89) 19F (13 to 82) 23F ( 3 to 78) 6A (12 to 79)
14 Meta-analysis PCV not efficacious against non-vaccine serotypes (excluding ST 6A) IPD in RCTrials Non-vaccine types excluding 6A Study RR (95% CI) Vaccine efficacy (%) NCKP (2000) Native American (2003) South Africa HIV - (2007) South Africa HIV + (2007) The Gambia (2005) Overall 0.60 (0.14, 2.51) 1.36 (0.52, 3.56) 3.50 (0.73, 16.84) 0.87 (0.43, 1.78) 1.00 (0.57, 1.74) 1.06 (0.74, 1.54) 40 (-151, 86) -36 (-256, 48) -250 (-900, 27) 13 (-78, 57) 0.0 (-74, 43) -6 (-54, 26) Risk ratio
15 Meta-analysis PCV not efficacious against serotype 19A IPD in RCTrials Serotype 19A, Study RR (95% CI) Vaccine efficacy (%) NCKP (2000) Native American (2003) South Africa HIV - (2007) South Africa HIV + (2007) The Gambia (2005) Overall (I-squared = 0.0%, p = 0.620) 0.33 (0.01, 8.19) 2.85 (0.12, 69.91) 3.00 (0.31, 28.83) 0.50 (0.13, 1.99) 0.86 (0.29, 2.55) 0.87 (0.43, 1.79) 66.6 (-718.7, 98.6) (-899.9, 88.4) (-899.9, 68.8) 50.0 (-99.2, 87.5) 14.3 (-154.9, 71.2) 12.8 (-78.5, 57.5) Risk ratio
16 Randomized controlled trials of PCV against pneumonia PCV-11 PCV-7 PCV-9 N =
17 What kind of pneumonia? WHO Pneumonia Vaccine Trial Investigators Group. Standardization of interpretation of chest radiographs for the diagnosis of pneumonia in children. WHO/V&B/01.35, Geneva 2001.
18 Diagnosing pneumococcal pneumonia Sensitivity Clinical criteria Modified criteria Any X-ray abnormality Alveolar consolidation Lung aspirate culture Blood culture Specificity
19 PCV efficacy is higher with a more specific diagnosis of pneumococcal pneumonia Specificity of pneumococcal pneumonia diagnosis High Low Clinical pneumonia Xray-confirmed pneumonia WHO-defined severe pneumonia Vaccine serotype-confirmed pneumonia Low PCV Efficacy High
20 PCV efficacy against pneumonia in RCTrials % VE USA NCKP 20 ZA HIV- 15 Gambia 10 Philippines 5 0 Xray+ Severe Clinical Pneumonia
21 PCV efficacious in reducing Xray confirmed pneumonia Trial PCV valency Incidence* Vaccinees Incidence* Controls Efficacy (95%CI) VPD** USA NCKP PCV-7 (5; 29) USA Native Am NA NA NA NA PCV-7 SA HIV Neg PCV-9 (3, 35) SA HIV Pos PCV-9 (-7, 28) The Gambia PCV-9 (25, 48) Philippines PCV-11 (-1, 41) *Per 1000 child years **Vaccine Preventable Disease Black S et al. PIDJ 2001/ Hansen PIDJ 2007; Klugman KP et al. NEJM 2003; Cutts F et al. Lancet 2005, O Brien, Lucero pers comm
22 The complicated relationship of observed vs. true efficacy of PCV against pneumococcal pneumonia # Cases Preventable Xray confirmed pneumonia 100 Pneumococcal Vaccine Serotype 50-70%? 50-70% Efficacy 50-70% Expected Effect Still cases of Xray confirmed pneumonia
23 Summary points PCV has - high efficacy against IPD - good efficacy against Xray confirmed pneumonia In addition, PCV has been found to reduce all-cause child mortality in a low-income country setting
24 Thank you to ARIVAC consortium GAVI ADIP Pneumo Thomas Cherian Terhi Kilpi Keith Klugman Shabir Madhi
Assessing public health impact through vaccine probe analyses. Robert F. Breiman Emory Global Health Institute Emory University
Assessing public health impact through vaccine probe analyses Robert F. Breiman Emory Global Health Institute Emory University State of understanding the relative role of pathogens in major disease syndromes
More informationEfficacy of Pneumococcal Conjugate Vaccines (PCV) against Otitis Media
Efficacy of Pneumococcal Conjugate Vaccines (PCV) against Otitis Media Terhi Kilpi National Public Health Institute Department of Vaccines 3rd Regional Pneumococcal Symposium 13 Feb 2008 Incidence of AOM
More informationTwo-in-one: GSK s candidate PHiD-CV dual pathogen vaccine
Two-in-one: GSK s candidate PHiD-CV dual pathogen vaccine Dr. Bernard Hoet Director, Medical affairs GlaxoSmithKline Biologicals Rixensart, Belgium Istanbul, Feb 13, 2008 PHiD-CV: A novel concept in Bacterial
More informationPneumococcal vaccines. Safety & Efficacy. Prof. Rajesh Kumar, MD PGIMER School of Public Health Chandigarh
Pneumococcal vaccines Safety & Efficacy Prof. Rajesh Kumar, MD PGIMER School of Public Health Chandigarh Disclosure Slide X X I DO NOT have any significant or other financial relationships with industry
More informationShabir A. Madhi. Progress and Challenges of Immunization Contributing Toward Attaining the MDG Goal to Reduce under-5 Childhood Mortality.
Shabir A. Madhi Progress and Challenges of Immunization Contributing Toward Attaining the MDG Goal to Reduce under-5 Childhood Mortality. National Institute for Communicable Diseases & University of Witwatersrand,
More informationPneumococcal Vaccine Effectiveness. Steven Black, MD Center for Global Health Cincinnati Children s s Hospital Cincinnati, Ohio USA
Pneumococcal Vaccine Effectiveness Steven Black, MD Center for Global Health Cincinnati Children s s Hospital Cincinnati, Ohio USA Overview Possible effectiveness outcomes for pneumococcal vaccines Pre-licensure
More informationThe effect of Haemophilus influenzae type b and pneumococcal conjugate vaccines on childhood pneumonia incidence, severe morbidity and mortality
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/ by-nc/2.5/) which permits unrestricted non-commercial
More informationEditorial. Pneumococcal Vaccination for Indian Children
Editorial Pneumococcal Vaccination for Indian Children Six years have passed since the last editorial on pneumococcal vaccines, written by Prof. Kim Mulholland, appeared in this journal(1). At that time,
More informationGlobal Evolution of the Pneumococcus and the Impact of Vaccination Keith P. Klugman
Global Evolution of the Pneumococcus and the Impact of Vaccination Keith P. Klugman Department of Global Health, Rollins School of Public Health and Division of Infectious Diseases, School of Medicine
More informationVaccine 25 (2007) University of the Witwatersrand/Medical Research Council, Respiratory and Meningeal Pathogens Research Unit, South Africa
Vaccine 25 (2007) 2413 2419 World Health Organisation definition of radiologically-confirmed pneumonia may under-estimate the true public health value of conjugate pneumococcal vaccines Shabir A. Madhi,
More informationCurrent Status of PCV Use and WHO Recommendations
Current Status of PCV Use and WHO Recommendations SAGE 18 October 2017 Kate O Brien, MD MPH 1 Pneumonia remains a major cause of child deaths LMIC LMIC Pneumonia HIC HIC Pneumonia ~16% ~5% 2015 Black,
More informationPneumococcal vaccines
Pneumococcal vaccines Marco Aurélio Sáfadi, MD, PhD FCM da Santa Casa de São Paulo Challenges in establishing the baseline burden of disease, before implementing a vaccination program S. pneumoniae disease
More informationSAGE pneumococcal conjugate vaccine working group
1 Detailed Review Paper on Pneumococcal Conjugate Vaccine - presented to the WHO Strategic Advisory Group of Experts (SAGE) on Immunization, November 2006 SAGE pneumococcal conjugate vaccine working group
More informationIID&GHTP. Pneumococcal vaccine Africa décembre By: Julie Lajoie
IID&GHTP Pneumococcal vaccine Africa décembre 2011 By: Julie Lajoie General information Ecology and Epidemiology of invasive pneumococcal disease (IPD) in sub Saharan Africa is different from that seen
More informationCONJUGATE VACCINES A BREAKTHROUGH IN VACCINE DEVELOPMENT
CONJUGATE VACCINES A BREAKTHROUGH IN VACCINE DEVELOPMENT P Helena Mäkelä National Public Health Institute, Helsinki, Finland Abstract. The encapsulated bacteria Streptococcus pneumoniae (the pneumococcus),
More informationORIGINAL ARTICLES. Pneumococcal conjugate vaccine a health priority. The burden of pneumococcal pneumonia. Heather J Zar, Shabir A Madhi
Pneumococcal conjugate vaccine a health priority Heather J Zar, Shabir A Madhi Pneumonia is a major cause of childhood mortality and morbidity. Streptococcus pneumoniae is the most important bacterial
More informationImpact of vaccination on epidemiology in adults
Impact of vaccination on epidemiology in adults Jan Verhaegen 1. Data on prospective study on IPD in Belgium (2009-2011) 2. Evolution of capsular types of invasive isolates from adults after introduction
More informationEffect of Introduction of Pneumococcal Conjugate Vaccine Immunization on. Nasopharyngeal Colonization of Streptococcus pneumoniae in South Africa
Effect of Introduction of Pneumococcal Conjugate Vaccine Immunization on Nasopharyngeal Colonization of Streptococcus pneumoniae in South Africa Susan Audrey Nzenze 464223 A thesis submitted to the Faculty
More informationSurveillance of invasive pneumococcal infection in Belgium
Surveillance of invasive pneumococcal infection in Belgium National Reference Laboratory Start in 198 Laboratory Microbiology UH Leuven (prof. J. Vandepitte) Capsular type determination Antibiotic susceptibility
More informationPneumococcal vaccination in UK: an update. Dr Richard Pebody Immunisation Department Health Protection Agency Centre for Infections
Pneumococcal vaccination in UK: an update Dr Richard Pebody Immunisation Department Health Protection Agency Centre for Infections Leading infectious causes of mortality, 2000 WHO estimates 3.5 Deaths
More informationImpact of pneumococcal conjugate vaccine: US experience Stephanie Schrag Centers for Disease Control and Prevention Atlanta, GA
Impact of pneumococcal conjugate vaccine: US experience Stephanie Schrag Centers for Disease Control and Prevention Atlanta, GA San Jose, Costa Rica, August 2007 Pneumococcal Conjugate Vaccine Introduction
More informationASSESSING THE VALUE OF VACCINE BEYOND EFFICACY AND SAFETY
ASSESSING THE VALUE OF VACCINE BEYOND EFFICACY AND SAFETY Bradford D. Gessner, MD Agence de Médecine Preventive First Regional Dengue Symposium Rio de Janeiro, Brasil November 3-4, 2015 BURDEN CONCEPTS
More informationCan infant vaccination prevent pneumococcal meningitis outbreaks in sub-saharan Africa?
Editorial Can infant vaccination prevent pneumococcal meningitis outbreaks in sub-saharan Africa? Author: James M Stuart, FFPH London School of Hygiene and Tropical Medicine, Keppel St, London WC1E 7HT,
More informationX THIS SUMMARY DOES NOT INCLUDE ! THIS SUMMARY INCLUDES
OPTIMIZING PNEUMOCOCCAL CONJUGATE VACCINES (PCV) SCHEDULES FOR CHILDREN IN VARIOUS AREAS OF THE WORLD What is the relative effect of administering PCV vaccines using a 3 primary doses (3p) versus 2 primary
More informationShabir A. Madhi. Global Overview of Maternal Immunisation
Shabir A. Madhi Global Overview of Maternal Immunisation National Institute for Communicable Diseases & University of Witwatersrand, South Africa Respiratory and Meningeal Pathogens Research Unit, & DST/NRF:
More informationImpact of different case definitions for acute otitis media on the efficacy estimates of a pneumococcal conjugate vaccine
Vaccine (2008) 26, 2466 2470 available at www.sciencedirect.com journal homepage: www.elsevier.com/locate/vaccine Impact of different case definitions for acute otitis media on the efficacy estimates of
More informationReview Article Pneumococcal Conjugate Vaccines and Otitis Media: An Appraisal of the Clinical Trials
International Journal of Otolaryngology Volume 2012, Article ID 312935, 15 pages doi:10.1155/2012/312935 Review Article Pneumococcal Conjugate Vaccines and Otitis Media: An Appraisal of the Clinical Trials
More informationRationale and design of CAPITA: a RCT of 13-valent conjugated pneumococcal vaccine efficacy among older adults
ORIGINAL ARTICLE Rationale and design of CAPITA: a RCT of 13-valent conjugated pneumococcal vaccine efficacy among older adults E. Hak 1,2*, D.E. Grobbee 1, E.A.M. Sanders 2, T.J.M. Verheij 1, M. Bolkenbaas
More informationPneumococcal Vaccines The Impact Of Conjugate Vaccine
Pneumococcal Vaccines The Impact Of Conjugate Vaccine 1 / 5 2 / 5 3 / 5 Pneumococcal Vaccines The Impact Of Pneumococcal vaccine. The pneumococcal vaccine protects against serious and potentially fatal
More informationvaccination. Children enrolled in these clusters between 6 weeks and 6 months of age received a 2-dose primary vaccination schedule.
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationInvasive Pneumococcal Disease in Kanti Children s Hospital, Nepal, as Observed by the South Asian Pneumococcal Alliance Network
SUPPLEMENT ARTICLE Invasive Pneumococcal Disease in Kanti Children s Hospital, Nepal, as Observed by the South Asian Pneumococcal Alliance Network A. S. Shah, 1 M. Deloria Knoll, 2 P. R. Sharma, 1 J. C.
More informationA Trial of a 9-Valent Pneumococcal Conjugate Vaccine in Children with and Those without HIV Infection
The new england journal of medicine original article A Trial of a 9-Valent Pneumococcal Conjugate Vaccine in Children with and Those without HIV Infection Keith P. Klugman, M.B., B.Ch., Ph.D., Shabir A.
More informationPneumococcal disease in sub-saharan African children: what is the effectiveness of the pneumococcal conjugate vaccine?
Pneumococcal disease in sub-saharan African children: what is the effectiveness of the pneumococcal conjugate vaccine? B Larrú Streptococcus pneumoniae is still a leading cause of morbidity and mortality
More informationExpanded Use of PCV13 & PPV23
Expanded Use of PCV13 & PPV23 Dr. Jim Kellner Professor & Head Department of Pediatrics University of Calgary & Calgary Zone, Alberta Health Services Jim.Kellner@ahs.ca Objectives Explain the differences
More informationCraig Laferriere. The selection of pneumococcal serotypes for a developing-world vaccine: A metaregression analysis of immunogenicity
Craig Laferriere The selection of pneumococcal serotypes for a developing-world vaccine: A metaregression analysis of immunogenicity I have no actual or potential conflict of interest in relation to this
More informationFull public health impact or. cherry-picking?
Full public health impact or cherry-picking? Arto Palmu, MD, PhD, Research manager, head of Clinical Research Team, Department of Public Health Solutions 10.11.2017 Arto Palmu / RIVM2017 1 Disclosure The
More informationImmunisation in people living with HIV. Dr Bernadett Gosnell, Department of Infectious Diseases, UKZN
Immunisation in people living with HIV Dr Bernadett Gosnell, Department of Infectious Diseases, UKZN Calculating immunisation s return on investment In Gavi-supported countries, 2011 2020 48x (full income
More informationPrevention of pneumococcal disease in Canadian adults Old and New. Allison McGeer, MSc, MD, FRCPC Mount Sinai Hospital University of Toronto
Prevention of pneumococcal disease in Canadian adults Old and New Allison McGeer, MSc, MD, FRCPC Mount Sinai Hospital University of Toronto Objectives Review epidemiology of pneumococcal disease in adults
More informationPneumococcal Disease and Pneumococcal Vaccines
Pneumococcal Disease and Epidemiology and Prevention of - Preventable Diseases Note to presenters: Images of vaccine-preventable diseases are available from the Immunization Action Coalition website at
More informationGSK Vaccine Development
GSK Vaccine Development Innovation and new technology to provide a solution Sub-regional Symposium on Pneumococcal in the Caribbean Dominican Republic, Oct 1-2 nd, 2008 Alejandro Lepetic, MD Medical Affairs
More informationIMPORTANCE OF VACCINE PREVENTABLE DISEASE INCIDENCE. Bradford D. Gessner, MD Agence de Médecine Preventive
IMPORTANCE OF VACCINE PREVENTABLE DISEASE INCIDENCE Bradford D. Gessner, MD Agence de Médecine Preventive Vaccine Launches 2013 2 Disease burden has been consistently mentioned by policymakers in countries
More informationTHE ROLE OF DISEASE BURDEN IN THE DECISION MAKING PROCESS: THE HIB VACCINE EXPERIENCE. Brad Gessner, MD Agence de Médecine Preventive
THE ROLE OF DISEASE BURDEN IN THE DECISION MAKING PROCESS: THE HIB VACCINE EXPERIENCE Brad Gessner, MD Agence de Médecine Preventive INDUSTRIALIZED COUNTRIES Meningitis incidence per 1 0 0 K per year 1970s:
More informationVACCINE IMPACT AND VALUE OF VACCINATION LOOKING AT BENEFITS BEYOND EFFICACY AND SAFETY
VACCINE IMPACT AND VALUE OF VACCINATION LOOKING AT BENEFITS BEYOND EFFICACY AND SAFETY Bradford D. Gessner Vaccinology 2017 III International Symposium for Asia Pacific Experts Hanoi, Vietnam October 16-18,
More informationI mun u i n s i atio i n o n u p u d p a d te
Immunisation update Brian Eley Paediatric Infectious Diseases Unit Red Cross War Memorial Children s Hospital Department of Paediatrics and Child Health University of Cape Town Immunisation schedules,
More informationNew evidence on intervention efficacy & effectiveness. Betty Kirkwood London School of Hygiene & Tropical Medicine
New evidence on intervention efficacy & effectiveness Betty Kirkwood London School of Hygiene & Tropical Medicine New research evidence Introduction What s new since Countdown 2008 Child survival (Betty
More informationCarga global de la enfermedad neumocócia
Carga global de la enfermedad neumocócia Ann R. Thomas, MD MPH Public Health Division Portland, Oregon Caracas, Venezuela, January 2008 Acknowledgements to Adam Cohen, CDC Principales Causas de Muertes
More informationExecutive Summary SAGE October 2017, Pneumococcal Conjugate Vaccine Session
1 Executive Summary SAGE October 2017, Pneumococcal Conjugate Vaccine Session 1.0 Introduction Currently, WHO has recommended the use of either a 10-valent or 13-valent pneumococcal conjugate vaccine (PCV10
More informationBacterial diseases caused by Streptoccus pneumoniae in children
Bacterial diseases caused by Streptoccus pneumoniae in children Bactermia 85% Bacterial pneumonia 66% Bacterial meningitis 50% Otitis media 40% Paranasal sinusitis 40% 0% 10% 20% 30% 40% 50% 60% 70% 80%
More informationPart I: Target Product Profile (TPP) for the Advance Market Commitment (AMC) for Pneumococcal Conjugate Vaccines Master Table
Part I: Target Product Profile (TPP) for the Advance Market Commitment (AMC) for Pneumococcal Conjugate Vaccines Master Table The product specifications tabled below are called the target product profile
More informationStreptococcus pneumoniae CDC
Streptococcus pneumoniae CDC Pneumococcal Disease Infection caused by the bacteria, Streptococcus pneumoniae» otitis media 20 million office visits (28-55% Strep)» pneumonia 175,000 cases annually» meningitis
More informationCUMULATIVE INVASIVE PNEUMOCOCCAL DISEASE CASE NUMBERS REPORTED BY THE GERMS-SA SURVEILLANCE PROGRAMME, 2005 TO DATE
CUMULATIVE INVASIVE PNEUMOCOCCAL DISEASE CASE NUMBERS REPORTED BY THE GERMS-SA SURVEILLANCE PROGRAMME, 5 TO DATE GERMS-SA surveillance programme http://www.nicd.ac.za/?page=germs-sa&id=97 National, active,
More informationDescribing the Epidemiology and Aetiology of Bacterial Pneumonia in Children: An Unresolved Problem
J HEALTH POPUL NUTR 2005 Mar;23(1):1 _ 5 2005 ICDDR,B: Centre for Health and Population Research ISSN 1606-0997 $ 5.00+0.20 EDITORIAL Describing the Epidemiology and Aetiology of Bacterial Pneumonia in
More informationStreptococcus pneumoniae is a major etiology of serious bacterial infection among children
Focused Issue of This Month Direct and Indirect Effects of Pneumococcal Protein Conjugate Vaccine Eunhwa Choi, MD Department of Pediatrics, Seoul National University College of Medicine E mail : eunchoi@snu.ac.kr
More informationHelsinki Carriage Workshop Kirkkonummi, Finland, June 27 th -29 th, 2007
Helsinki Carriage Workshop Kirkkonummi, Finland, June 27 th -29 th, 2007 Program Overview Wednesday (June 27 th ) Breakfast (7:00 a.m. 9:00 a.m.) A. Opening session (9:00 a.m. 9:30 a.m.) B. Biology of
More informationPneumococcal Vaccine Introductions Dr. Carsten Mantel WHO/FCH/IVB/EPI
Pneumococcal Vaccine Introductions 2012 Dr. Carsten Mantel WHO/FCH/IVB/EPI Pneumonia is leading cause of death in children < 5 yrs * Pneumococcus and Hib are the two leading causes of life-threatening
More informationFaculty Disclosure. Stephen I. Pelton, MD. Dr. Pelton has listed no financial interest/arrangement that would be considered a conflict of interest.
Faculty Disclosure Stephen I. Pelton, MD Dr. Pelton has listed no financial interest/arrangement that would be considered a conflict of interest. Advances in the management of fever in infants 0 to 3 and
More informationThe Gates Challenge. Bill Gates Commencement Address Harvard University Class of 2007
History & Future of the Expanded Programme on Immunization Supplier Meeting, Copenhagen, 3-4 April 2008 Dr Osman David Mansoor Senior Adviser EPI (New Vaccines) UNICEF New York The Gates Challenge If we
More informationHaemophilus influenzae
Haemophilus influenzae type b Severe bacterial infection, particularly among infants During late 19th century believed to cause influenza Immunology and microbiology clarified in 1930s Haemophilus influenzae
More informationEpidemiology and clinical features of pneumonia according to radiographic findings in Gambian children
Tropical Medicine and International Health doi:10.1111/j.1365-3156.2007.01922.x volume 12 no 11 pp 1377 1385 november 2007 Epidemiology and clinical features of according to radiographic findings in Gambian
More informationMonitoring results: goals, strategic objectives and indicators
page 108 Monitoring results: goals, strategic objectives and indicators 6. SURVEILLANCE Strategic Objective 4: strong immunization sytems are an integral part of a well-functioning health system. Indicator
More informationDetermining the size of a vaccine trial
17th Advanced Vaccinology Course Annecy 26 th May 2016 Determining the size of a vaccine trial Peter Smith London School of Hygiene & Tropical Medicine Purposes of lecture Introduce concepts of statistical
More informationUpdate on Implementation of NUV. Carsten Mantel WHO/FCH/IVB/EPI
Update on Implementation of NUV Carsten Mantel WHO/FCH/IVB/EPI Introduction of New Vaccines The continuum of activity REGULATORY NORMS & STANDARDS VACCINE SUPPLY PROCUREMENT PRICING FINANCING SURVEILLANCE
More informationACIP Recommendations for Pneumococcal 13-valent Conjugate and 23-valent Polysaccharide Vaccine Use among Adults
ACIP Recommendations for Pneumococcal 13-valent Conjugate and 23-valent Polysaccharide Vaccine Use among Adults National Center for Immunization & Respiratory Diseases Respiratory Diseases Branch ACIP
More informationImpacto de la vacuna conjugada en EUA
Impacto de la vacuna conjugada en EUA Richard Facklam, PhD, Distinguished Consultant, Retired, Centers for Disease Control and Prevention Atlanta, GA Bogotá, Colombia, February 2008 Pneumococcal Conjugate
More informationMAJOR ARTICLE. J. Anthony G. Scott, 1,2 John Ojal, 1 Lindsey Ashton, 3 Anne Muhoro, 1 Polly Burbidge, 3 and David Goldblatt 3
MAJOR ARTICLE Pneumococcal Conjugate Vaccine Given Shortly After Birth Stimulates Effective Antibody Concentrations and Primes Immunological Memory for Sustained Infant Protection J. Anthony G. Scott,,
More informationBenefits of the pneumococcal immunisation programme in children in the United Kingdom
Benefits of the pneumococcal immunisation programme in children in the United Kingdom 2006-2014 Professor Mary P E Slack mpeslack@gmail.com March 2015 Disclosure of interest The presenter has received
More information14/10/16. Background. Streptococcus pneumoniae (Sp) is an important cause for these diseases
Estimates of the potential public health impact and cost-effectiveness of adopting pneumococcal vaccination in the routine immunization programme in African GAVI countries: a modelling study C. Sauboin
More information"Non-invasive Pneumococcal Diseases dynamics & the Host Age" Roman Prymula Ministry of Health, the Czech Republic
"Non-invasive Pneumococcal Diseases dynamics & the Host Age" Roman Prymula Ministry of Health, the Czech Republic Disease Caused by S. pneumoniae S. pneumoniae Eustachian Tube Nasopharynx Pharynx Nasal
More informationDr Stewart Reid. General Practitioner Ropata Medical Centre Wellington
Dr Stewart Reid General Practitioner Ropata Medical Centre Wellington 7:15-8:10 Medicines New Zealand Breakfast Session Adult Vaccination The Poor Cousin Adult Vaccination The poor cousin Stewart Reid
More informationEXECUTIVE SUMMARY MEDICAL BACKGROUND
Pneumococcal Conjugate Vaccine for Young Children SHARON SELMAN*, DIANE HAYES*, LAWRENCE A. PERIN*, WINIFRED S. HAYES* *Hayes Inc.; School of Medicine and Biomedical Sciences, State University of New York
More informationShabir A. Madhi Possibilities for reducing neonatal and young infant mortality through Maternal immunization
Shabir A. Madhi Possibilities for reducing neonatal and young infant mortality through Maternal immunization National Institute for Communicable Diseases & University of Witwatersrand, South Africa Respiratory
More informationTHE IMPORTANCE OF THE FULL PUBLIC HEALTH VALUE OF VACCINATION IN DECISIONS OF POLICY MAKERS: WHERE DO WE STAND AND WHERE SHOULD WE GO?
THE IMPORTANCE OF THE FULL PUBLIC HEALTH VALUE OF VACCINATION IN DECISIONS OF POLICY MAKERS: WHERE DO WE STAND AND WHERE SHOULD WE GO? Brad Gessner, MD Agence de Médecine Preventive DECISION MAKING Vaccine
More informationPotential public health impact of RSV vaccines. R. Karron December 2016
Potential public health impact of RSV vaccines R. Karron December 2016 1. RSV is The leading cause of hospitalization in infants and in many high-income countries; >2 million medical visits annually in
More informationIncidence per 100,000
Streptococcus pneumoniae Surveillance Report 2005 Oregon Active Bacterial Core Surveillance (ABCs) Office of Disease Prevention & Epidemiology Oregon Department of Human Services Updated: March 2007 Background
More informationRespiratory infections in the elderly: epidemiology and prevention strategies. Mike Jackson Kaiser Permanente Washington 22 March 2017
Respiratory infections in the elderly: epidemiology and prevention strategies Mike Jackson Kaiser Permanente Washington 22 March 2017 Conflicts of interest I have received a research grant from Sanofi
More informationsamedi 17 octobre 2009 MJA 2009, 191:142
1 MJA 2009, 191:142 2 MJA 2009, 191:142 3 4 CDC Interim Recommendations for Oseltamivir and Zanamivir Patient Categories for Treatment 1.Recommended: all patients hospitalized with suspected or confirmed
More informationReport of Typing & Antimicrobial Susceptibilities of Isolates Causing Invasive Pneumococcal Disease in Ireland,
Report of Typing & Antimicrobial Susceptibilities of Isolates Causing Invasive Pneumococcal Disease in Ireland, 2011-2013 1. Background Streptococcus pneumoniae is a major cause of life-threatening infections
More informationTransmission of Streptococcus pneumoniae in Rural Gambian Villages: A Longitudinal Study
MAJOR ARTICLE Transmission of Streptococcus pneumoniae in Rural Gambian Villages: A Longitudinal Study Philip C. Hill, 1,2 John Townend, 1 Martin Antonio, 1 Biodun Akisanya, 1 Chinelo Ebruke, 1 George
More information9/12/2018. Pneumococcal Disease and Pneumococcal Vaccines. Streptococcus pneumoniae. Pneumococcal Disease. Adult Track. Gram-positive bacteria
Centers for Disease Control and Prevention National Center for Immunization and Respiratory Diseases Pneumococcal Disease and Pneumococcal Vaccines Adult Track Chapter 17 Photographs and images included
More informationExperience with maternal pertussis and PCV13 immunisation in England
Experience with maternal pertussis and PCV13 immunisation in England Immunisation, Hepatitis & Blood Safety department Public Health England 5th RIVM Vaccine Preventable Diseases Research day 18 th November
More informationStreptococcus pneumoniae can cause a variety of clinical syndromes
Supplement Systematic Review of the Effect of Pneumococcal Conjugate Vaccine Dosing Schedules on Vaccine-type Invasive Pneumococcal Disease Among Young Children Laura Conklin, MD,* Jennifer D. Loo, MPH,*
More informationUsing a mathematical model to evaluate the impact of different PCV schedules:
Using a mathematical model to evaluate the impact of different PCV schedules: Preliminary results from the West Africa epidemiological scenario Alessia Melegaro 1, Albert Jan van Hoek 2, Yoon Choi 2, Nigel
More informationPneumococcal disease: Global burden, epidemiology, scope for vaccine prevention
Pneumococcal disease: Global burden, epidemiology, scope for vaccine prevention Stephanie Schrag Centers for Disease Control and Prevention Atlanta, GA San Jose, Costa Rica, August 2007 Pneumococcal Carriage
More information2016 Vaccine Preventable Disease Summary
2016 Vaccine Preventable Disease Summary 12251 James Street Holland, MI 49424 www.miottawa.org/healthdata Prepared October 2017 2016 Summary of Vaccine Preventable Diseases (VPDs) Reported to Ottawa County
More informationCarga global de la enfermedad neumocócia Adam L. Cohen, MD MPH Centers for Disease Control and Prevention Atlanta, GA
Carga global de la enfermedad neumocócia Adam L. Cohen, MD MPH Centers for Disease Control and Prevention Atlanta, GA Santiago, Chile, December 2007 Pneumococcal Carriage and Disease Ear infections Meningitis
More information2 o Strengthening the Global IB VPD Laboratory Network. 2 o Ensuring Adherence to Case Definitions
Global Invasive Bacterial Vaccine Preventable Diseases (IB VPD) Information and Surveillance Bulletin Volume 3: April 2011 The World Health Organization (WHO) produces this twice-yearly global IB VPD Information
More informationPotential Impact of Conjugate Vaccine on the Incidence of Invasive Pneumococcal Disease among Children in Scotland
JOURNAL OF CLINICAL MICROBIOLOGY, Apr. 2006, p. 1224 1228 Vol. 44, No. 4 0095-1137/06/$08.00 0 doi:10.1128/jcm.44.4.1224 1228.2006 Copyright 2006, American Society for Microbiology. All Rights Reserved.
More informationPneumoccocal vaccines in the elderly (conjugated vs polysaccharides)
Aging and Immunity II Campus Novartis, Siena April 24, 2012 Pneumoccocal vaccines in the elderly (conjugated vs polysaccharides) Paolo Bonanni Department of Public Health University of Florence, Italy
More informationBurden of disease caused by Streptococcus pneumoniae in children younger than 5 years: global estimates
Burden of disease caused by Streptococcus pneumoniae in children younger than 5 years: global estimates Katherine L O Brien, Lara J Wolfson, James P Watt, Emily Henkle, Maria Deloria-Knoll, Natalie McCall,
More informationSYNFLORIX TM. adsorbed on aluminium phosphate 0.5 milligram Al conjugated to protein D (derived from NTHi) carrier protein 9-16 micrograms 3
1. NAME OF THE MEDICINAL PRODUCT SYNFLORIX TM Synflorix TM suspension for injection Pneumococcal polysaccharide conjugate vaccine (adsorbed) 2. QUALITATIVE AND QUANTITATIVE COMPOSITION 1 dose (0.5 ml)
More information...REPORTS... Epidemiology of Pneumococcal Disease/ Rationale for and Efficacy of PnC7
...REPORTS... Epidemiology of Pneumococcal Disease/ Rationale for and Efficacy of PnC7 Summary A Streptococcus pneumoniae Conjugate Vaccine Managed Care Advisory Panel was presented with information on
More informationShabir A Madhi Director: National Institute for Communicable Disease & Medical Research Council: Respiratory and Meningeal Pathogens Research Unit
Shabir A Madhi Director: National Institute for Communicable Disease & Medical Research Council: Respiratory and Meningeal Pathogens Research Unit » 45% (2.7 million) of under-5 deaths occurred in first
More informationPr Robert Cohen CHI Créteil France
EFFECT OF VACCINATION ON ANTIMICROBIAL RESISTANCE : THE EXAMPLE OF THE IMPACT OF PCVS ON ANTIBIOTIC RESISTANCE Pr Robert Cohen CHI Créteil France 1 DISCLOSURES I have received during the las 3 years honorarium
More informationGlobal Invasive Bacterial Vaccine-Preventable Diseases Surveillance
Global Invasive Bacterial Vaccine-Preventable Diseases Surveillance-2008-2014 Jillian Murray, World Health Organization (WHO) Mary Agocs, World Health Organization (WHO) Fatima Serhan, World Health Organization
More informationSynflorix. Pneumococcal polysaccharide and Non-Typeable Haemophilus influenzae (NTHi) protein D conjugate vaccine, adsorbed
Synflorix Pneumococcal polysaccharide and Non-Typeable Haemophilus influenzae (NTHi) protein D conjugate vaccine, adsorbed QUALITATIVE AND QUANTITATIVE COMPOSITION One dose (0.5 ml) contains 1 microgram
More informationby author ESCMID Online Lecture Library Steroids in acute bacterial meningitis
Steroids in acute bacterial meningitis Javier Garau, MD, PhD University of Barcelona Spain ESCMID Summer School, Porto, July 2009 Dexamethasone treatment in childhood bacterial meningitis in Malawi: a
More informationNEW ZEALAND DATA SHEET
NEW ZEALAND DATA SHEET 1. PRODUCT NAME SYNFLORIX pneumococcal polysaccharide conjugate vaccine, 10 valent adsorbed. Suspension for injection. 2. QUALITATIVE AND QUANTITATIVE COMPOSITION 1 dose (0.5 ml)
More informationInfluenza endpoints during clinical trials
Influenza endpoints during clinical trials Bradford D. Gessner for the influenza endpoints working group Abdullah Baqui Punam Mangtani Richard Wunderink Thomas Cherian Hanna Nohynek Michael Jackson Jeff
More informationImpact of Universal Infant Immunization with Pneumococcal (Streptococcus pneumonia) Conjugate Vaccines in Alaska
Pacific University CommonKnowledge School of Physician Assistant Studies Theses, Dissertations and Capstone Projects 8-2008 Impact of Universal Infant Immunization with Pneumococcal (Streptococcus pneumonia)
More informationPNEUMONIA : PROMISE FULFILLED? Regina Berba MD FPSMID
PNEUMONIA : PROMISE FULFILLED? Regina Berba MD FPSMID Objectives of Lecture Know the quality of current evidence based guidelines on immunization Appreciate the performance of pneumonia vaccines in terns
More information